文献速递前列腺癌

携带致病性BRCA2突变的转移性前列腺癌孤立性腹膜癌病:细胞减灭术联合腹腔热灌注化疗新病例

Novel Case of Isolated Peritoneal Carcinomatosis from Metastatic Prostate Cancer Carrying a Pathogenic BRCA Mutation Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.
PubMed 文献 · Urology · 2021-05-25

本文报道首例携带既往未报告致病性BRCA2突变的转移性前列腺癌孤立性腹膜癌病(无其他器官受累)患者。CT显示腹膜癌病且无腹膜外转移,治疗包括新辅助化疗、细胞减灭术联合腹腔热灌注化疗(CRS/HIPEC)及辅助化疗。患者30个月无病生存。胚系基因检测显示BRCA2 c.1813dupA(p.I605Nfs*11)突变,肿瘤基因组检测还发现TMPRSS2、TBX3和TP53突变。鉴于其表现和BRCA突变谱与卵巢癌相似,BRCA2突变可能 contribute 于疾病表型,CRS/HIPEC可能为该独特转移模式提供长期获益。

要点

  • 首例携带致病性BRCA2突变的前列腺癌孤立性腹膜癌病,无其他器官转移。
  • 采用新辅助化疗、CRS/HIPEC及辅助化疗,患者30个月无病生存。
  • 肿瘤基因组检测发现TMPRSS2、TBX3和TP53突变,BRCA2突变可能与疾病表型相关。

核心结论

  • 对于携带致病性BRCA2突变的转移性前列腺癌孤立性腹膜癌病患者,CRS/HIPEC联合化疗可能提供长期无病生存。

研究设计与样本

  • 单病例报告,描述一例转移性前列腺癌孤立性腹膜癌病患者的诊断、基因检测和治疗过程。

主要发现

  • CT显示腹膜癌病且无腹膜外转移。
  • 患者接受新辅助化疗、CRS/HIPEC及辅助化疗后30个月无病生存。
  • 胚系基因检测显示BRCA2 c.1813dupA(p.I605Nfs*11)突变,肿瘤基因组检测发现TMPRSS2、TBX3和TP53突变。

临床怎么用

  • 对转移性前列腺癌患者出现孤立性腹膜癌病时,可考虑进行胚系和肿瘤基因组检测以识别BRCA2等突变。
  • CRS/HIPEC可作为该独特转移模式的多模式治疗选择之一,但需个体化评估。

局限性

  • 仅为单例病例报告,结论的普遍性有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

We present the first case of isolated peritoneal carcinomatosis (PC) from prostate cancer carrying a previously unreported pathogenic BRCA2 mutation without other organ involvement. CT showed PC with no extra-peritoneal metastases. Treatment included neoadjuvant chemotherapy, cytoreductive surgery/hyperthermic intraperitoneal chemotherapy (CRS/HIPEC), and adjuvant chemotherapy. Patient is disease-free after 30-months. Germline genetic testing showed BRCA2 c.1813dupA (p.I605Nfs*11) mutation, reported in breast and ovarian cancers. Tumor genomic testing also revealed TMPRSS2, TBX3, and TP53 mutations. Given the comparable presentation and BRCA-mutation profile to ovarian cancer, BRCA2 mutations may contribute to disease phenotypes. CRS/HIPEC may provide long-term outcomes for this unique metastatic pattern.

来源:Urology,查看原文。版权归原作者所有。

引用

  1. King MC, Sardi A, Velez-Mejia C, et al. Novel Case of Isolated Peritoneal Carcinomatosis from Metastatic Prostate Cancer Carrying a Pathogenic BRCA Mutation Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy. Urology. 2021. PMID: 34048828. doi:10.1016/j.urology.2021.05.026

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。